Results 221 to 230 of about 4,521,628 (366)

Cost‐effectiveness analysis of a digital diabetes‐prevention programme versus an in‐person diabetes‐prevention programme in people with prediabetes in the United States [PDF]

Sooyeol Park, Jeromie Ballreich, Trevor Ward, Lizheng Shi   +3 more
openalex   +1 more source

Diffusion Spectrum Imaging Maps Early Axonal Loss and a Unique Progressive Signal in Neuronal Intranuclear Inclusion Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To delineate specific in vivo white matter pathology in neuronal intranuclear inclusion disease (NIID) using diffusion spectrum imaging (DSI) and define its clinical relevance. Methods DSI was performed on 42 NIID patients and 38 matched controls.
Kaiyan Jiang, Yixiu Pei, Xiaobao Hu, Ying Xiong, Fang Wang, Yanyan Yu, Min Zhu, Dandan Tan, Meihong Zhou, Daojun Hong, Fuqing Zhou   +10 more
wiley   +1 more source

Cost-Effectiveness Analysis of Pitavastatin in Dyslipidemia: Vietnam Case. [PDF]

Healthcare (Basel)
Vo NX, Nguyen HTM, Phan NM, Pham HL, Bui TT, Bui TT.   +5 more
europepmc   +1 more source

PNR1: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

, 2000
Ewa Orlewska, Paweł Mierzejewski, Anna Członkowska   +2 more
openalex   +1 more source

Feasibility and Tolerability of Performing Portable MRI for Neurological Disorders in an Outpatient Neurology Clinic: A Prospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Accessing brain magnetic resonance imaging (MRI) can be challenging, especially for underserved patients, which may lead to disparities in neurological diagnosis. Method This mixed‐methods study enrolled adults with one of four neurological disorders: mild cognitive impairment or dementia of the Alzheimer type, multiple sclerosis ...
Maya L. Mastick, Nomin Enkhtsetseg, Joseph Sadok, Matheus Mochetti, Annabel Sorby Adams, Jennifer Guo, Cristina Trapaga Hacker, Isabella Gomez Hjerthen, Seungwon Lee, Siddharth Satish, Andrew S. Ham, Justin Hill, Denis Balaban, Kevin Kyle, Rebecca L. Gillani, Marcelo Matiello, Aleksandar Videnovic, Eric C. Klawiter, W. Taylor Kimberly, Farrah J. Mateen   +19 more
wiley   +1 more source

Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.

Value in Health, 2015
S. Ramsey, R. Willke, H. Glick, S. Reed, F. Augustovski, B. Jônsson, A. Briggs, S. Sullivan   +7 more
semanticscholar   +1 more source

Modeled cost-effectiveness analysis of autologous haemopoietic stem cell transplantation compared with standard dose chemotherapy for relapsed, aggressive non-Hodgkin’s lymphoma [PDF]

, 2005
J. Prajogo, Philip A. Rowlings, Amanda L. Neil, Janine M. Duke, H. Zhang, Barrie Stokes   +5 more
openalex   +1 more source

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher, Charles B. Malpas, Stuart J. McDonald, William T. O’Brien, Craig Despott, Kelly L. Bertram, Matthew P. Pase, Lukas Frontzkowski, Meng Law, Terence J. O’Brien, Lucy Vivash   +10 more
wiley   +1 more source

Geriatric Helpline Services to Improve Health and Care Pathways in Older Adults: A Cost-Effectiveness Analysis. [PDF]

Health Sci Rep
Mourgues C, Bongue B, Dupré C, Goethals L, Celarier T, Blanquet M.   +5 more
europepmc   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source